A comparison of treated vs untreated patients with MDS with a sample size of approximately 8000 patients in 11 countries.
Non-interventional multicentre retrospective study using chart reviews - study was submitted to the ethics committee of city of Vienna - due to the design of the study no specific approval necessary. Inclusion of MDS (all subtypes and risk groups) patients according to WHO or oligoblastic AML (RAEB-T according to FAB), untreated and treated during their chronic MDS phase The 26 centers of the IWG-PM have provided control data set of untreated, all centers will be asked for contribution of treated patients Data will be collected in Austria, Brazil, Czech Republic, France, Germany, Italy, Japan, Netherlands, Spain, UK, USA.
Study Type
OBSERVATIONAL
Enrollment
9,179
Hanusch Krankenhaus, 3.Medizinische Abteilung
Vienna, Austria
1.Overall Survival
In \*overall survival\* two possible events are defined: * \*death\* (regarded as complete observation) * \*end of follow up\* (regarded as censored observation) Time is calculated from diagnosis to the first occurrence of one of the above listed events.
Time frame: From date of diagnosis until the date of death or lost to follow-up, whichever came first. No administrative censoring will be applied to the retrospectively collected data, a minimum period of two months of stable disease will be required.
2.Time to transformation
In \*time to transformation\* three possible events are defined: * \*transformation into AML\* (regarded as complete observation) * \*death without transformation\* (regarded as censored observation) * \*end of follow up\* (regarded as censored observation) Time is calculated from diagnosis to the first occurrence of one of the above listed events. In case of \*transformation into AML\* this results in a complete observation, in case of \*death without transformation\* or \*end of follow up\* the observation is treated as censored.
Time frame: From date of diagnosis until the date of transformation,death or lost to follow-up, whichever came first. No administrative censoring will be applied to the retrospectively collected data,a minimum period of two months of stable disease will be required.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.